A new study has been published looking at the effects of treating COVID-19 patients with hydroxychloroquine.
Title: “Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial”
Authors: Zhaowei Chen, Jijia Hu, Zongwei Zhang, Shan Jiang, Shoumeng Han, Dandan Yan, Ruhong Zhuang, Ben Hu, Zhan Zhang
doi: https://doi.org/10.1101/2020.03.22.20040758
Link to study: https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2
From the abstract
“No difference in the age and sex distribution between the control group and the HCQ group. But for TTCR [Time to clinical recovery], the body temperature recovery time and the cough remission time were significantly shortened in the HCQ treatment group. Besides, a larger proportion of patients with improved pneumonia in the HCQ treatment group (80.6%, 25 of 32) compared with the control group (54.8%, 17 of 32). Notably, all 4 patients progressed to severe illness that occurred in the control group. However, there were 2 patients with mild adverse reactions in the HCQ treatment group. Significance: Among patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia.” (Emphasis added)